An estimated 3.2 million new cancer cases and 1.7 million deaths per year in Europe define cancer as a crucial public health problem. The SaveMe project funded under the EU's FP7 Program is addressing major urgent needs for cancer diagnosis and treatment by design and development of a novel modular nanosystems platform integrating advanced functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems for diagnostic or therapeutic applications as defined by their active agent compositions. For the early diagnosis of pancreatic cancer Somatostatin and Galectin-1 receptors (SSTR and Gal-1/tPA) will be utilized for targeting the tumor and visualization by PET, MRI or combined scanning. Similarly labeled nanoparticles containing specific antibodies or silencing RNA directed against the tumor will be used for advanced therapeutics.
L. Shenkman, M. Comes Franchini (2012). A modular nanosystems platform for advanced cancer management. LA CHIMICA E L'INDUSTRIA, 16, 110-113.
A modular nanosystems platform for advanced cancer management
COMES FRANCHINI, MAURO
2012
Abstract
An estimated 3.2 million new cancer cases and 1.7 million deaths per year in Europe define cancer as a crucial public health problem. The SaveMe project funded under the EU's FP7 Program is addressing major urgent needs for cancer diagnosis and treatment by design and development of a novel modular nanosystems platform integrating advanced functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems for diagnostic or therapeutic applications as defined by their active agent compositions. For the early diagnosis of pancreatic cancer Somatostatin and Galectin-1 receptors (SSTR and Gal-1/tPA) will be utilized for targeting the tumor and visualization by PET, MRI or combined scanning. Similarly labeled nanoparticles containing specific antibodies or silencing RNA directed against the tumor will be used for advanced therapeutics.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
